Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05957367 · ClinicalTrials.gov registry record · Phase 1
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A Phase 1 study of GIST, sponsored by Deciphera Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 14
- Study locations
NCT05957367 is a Phase 1 study of GIST that is actively recruiting participants, run by Deciphera Pharmaceuticals. The registered enrollment target is 94 participants, below the 124-participant average among 8 other GIST trials with a reported enrollment target (24% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT05957367, a Phase 1 study of GIST, is actively recruiting participants, sponsored by Deciphera Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Conditions Studied
Interventions
- DRUG Inlexisertib
- DRUG Ripretinib
Study Locations (14)
Other
- Antonie Van Leeuwenhoek Hospital - Amsterdam
- Radboudumc - Nijmegen
- Inselspital Universitätsklinikum Bern - Bern
California
- University of Southern California - Norris Comprehensive Cancer Center - Los Angeles
- UCLA Department of Medicine-Hematology/Oncology - Los Angeles
Florida
- Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- University of Massachusetts Worcester - Worcester
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University School of Medicine - Siteman Cancer Center - St Louis
New York
- Memorial Sloan Kettering Cancer Center - Main Campus - New York
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05957367
The ClinicalTrials.gov registry entry for NCT05957367 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 8 other GIST trials with a reported enrollment target (24% lower). The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST appearing as the primary indexed condition, and to 2 interventions - of which Inlexisertib is the first listed.
NCT05957367 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05957367 about?
NCT05957367 is a clinical study titled "A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies". This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
What is the current status of trial NCT05957367?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-09-28. Estimated completion is 2029-03.
What conditions does trial NCT05957367 study?
This clinical trial studies the following conditions: GIST.
What interventions are being tested in trial NCT05957367?
The interventions under investigation include: Inlexisertib (DRUG), Ripretinib (DRUG).
Who is sponsoring clinical trial NCT05957367?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05957367 being conducted?
This trial has 14 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GIST
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RECRUITING · Phase 1
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
-
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.